

What is claimed is:

Claim 1. A method of inhibiting the loss of the active enantiomers of a chiral drug in a carrier composition of a transdermal system, comprising the steps of:

providing a laminate package material comprising:

- (i) an inner layer comprising a thermoplastic polymer film, wherein said layer is free of polyolefins, metal foil and vinyl acetate; and
- (ii) an outer layer affixed to said inner layer;

providing a non-aqueous carrier composition of a transdermal system comprising a chiral drug or active enantiomers thereof that degrades or is unstable when exposed to vinyl acetate and metal foil materials;

placing said carrier composition within a pouch of the laminate packaging material; and
sealing said pouch along one or more edges of the inner layer, wherein the chiral drug or active enantiomers thereof excludes nicotine.

Claim 2. A method according to claim 1, wherein the inner layer of the laminate packaging material is self-sealing.

Claim 3. A method according to claim 1, wherein the inner layer is a film of rubber modified acrylonitrile methyl acrylate copolymers.

Claim 4. A method according to claim 3, wherein the outer layer comprises at least one polyester film affixed to the inner layer.

Claim 5. A method according to claim 4, wherein the outer layer is affixed to the inner layer by means of an adhesive.

Claim 6. A method according to claim 1, wherein the laminate packaging material is child resistant.

Claim 7. A method according to claim 1, wherein the laminate packaging material is translucent.

Claim 8. A method according to claim 1, wherein the chiral drug is selected from the group consisting of methylphenidate, a pharmaceutically acceptable salt or base of methylphenidate, and active enantiomers thereof.